JNJ 41876666 (JNJ-41876666) is a potent, selective, orally active TRPM8 channel antaognist with IC50 of 0.8 nM.
JNJ 41876666 exhibits minimal effect on the enzyme activity of CYP isoforms 3A4, 1A2, 2D6, 2C9, and 2C19 (IC50>10 uM).
JNJ 41876666 completely prevents icilin-induced WDS at an oral dose of 10 mg/kg, exhibits potent in vitro functional activity and robust oral efficacy in an inflammatory model of neuropathic pain at relatively low plasma levels.
JNJ 41876666 also reduces proliferation rates and proliferative fraction in prostate cancer cells.
